Survey of 204 IT leaders reveals that ServiceOps has evolved into a unified operational approach combining IT service, ITOps, and ESM with AI, automation, observability, and cross-team collaboration to align IT delivery with business value Enterprise Management Associates (EMA™), a leading IT research and consulting firm, has released a new report, “Redefining Modern Service Management: […]

Halper Sadeh LLC Encourages GDOT, BLFY, AXTA, GDEN Shareholders to Contact the Firm to Discuss Their Rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights GlobeNewswire November 25, 2025 NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating

Grand Opening of bonap: Alexis Nihon's New Food Court GlobeNewswire November 25, 2025 MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) — bonap, Alexis Nihon's new food court, is now open! The community can gather in the redesigned space to enjoy tasty moments in a fresh, inviting setting. “The creation of this new food court represents a

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

Targeting the Root Causes of Aging Demonstrates Powerful Anti-Cancer Activity Across Multiple Tumor Models Immorta Bio Inc., a scientific longevity company pioneering therapies focusing on Treating Diseases of Aging and Treating Aging as Disease™, today announced the publication of its international patent application PCT/WO2025184665[1], entitled “Senescence Vaccine.” The application describes Immorta Bio's proprietary approach to

(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva's strong biosimilars portfolio, in line with Teva's Pivot to Growth

(NASDAQ:NNOX), Althea France, part of one of Europe's largest independent medical technology services providers, to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's fourth European distribution agreement following recent collaborations in Greece, Romania and Czech Republic PETACH TIKVA, ISRAEL – November 25, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the

National plaintiffs' law firm Berger Montague PCannounces a class action lawsuit against James Hardie Industries plc (NYSE: JHX) (“James Hardie” or the “Company”) on behalf of investors who purchased James Hardie common stock and American Depositary Shares during the period ofMay 20, 2025 through August 18, 2025 (the “Class Period”). https://mma.prnewswire.com/media/232479/berger_montague.jpg Investor Deadline: Investors who

Strategic acquisition will accelerate growth by embedding advanced multilingual AI across the Gloo platform Gloo (Nasdaq: GLOO), a technology platform serving the faith and flourishing ecosystem, announced it has acquired XRI Global, an AI company pioneering voice AI and multilingual technologies designed to engage people across thousands of languages. https://mma.prnewswire.com/media/2831576/XRI_Press_Release__1.jpg XRI's capabilities allow Gloo to

Teva receives European Commission approvals for PONLIMSI(R) (denosumab) Biosimilar to Prolia(R) and DEGEVMA(R) (denosumab) Biosimilar to Xgeva(R) GlobeNewswire November 25, 2025 Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva's biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments